Search results
Results from the WOW.Com Content Network
Herpes simplex research includes all medical research that attempts to prevent, treat, or cure herpes, as well as fundamental research about the nature of herpes. Examples of particular herpes research include drug development , vaccines and genome editing.
Human herpes virus One of the most notable functions of this virus family is their ability to enter a latent phase and lay dormant within animals for extended periods of time. [ 1 ] The mechanism that controls this is very complex because expression of viral proteins during latency is decreased a great deal, meaning that the virus must have ...
Herpes simplex 2, the virus usually responsible for genital herpes, can cause oral herpes infections, too—you might imagine how. Once infected with oral herpes, most people show no symptoms ...
Herpes simplex viruses have also been studied in the central nervous system disorders such as multiple sclerosis, but research has been conflicting and inconclusive. [85] Following a diagnosis of genital herpes simplex infection, patients may develop an episode of profound depression. In addition to offering antiviral medication to alleviate ...
More than 3.7 billion people under the age of 50 suffer from the herpes simplex virus type 1 (HSV-1), usually after catching it in childhood. You probably have herpes, the WHO says Skip to main ...
This species appears to be particularly damaging to the nervous system, and some research has attributed Herpes simplex virus 1 infection to an increased risk of developing Alzheimer's disease. The virus interacts with the components and receptors of lipoproteins, which may lead to the development of Alzheimer's disease. [7]
Herpes simplex, often known simply as herpes, is a viral infection caused by the herpes simplex virus. [5] Herpes infections are categorized by the area of the body that is infected. The two major types of herpes are oral herpes and genital herpes , though other forms also exist.
Pritelivir (development codes AIC316 or BAY 57-1293) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV). This is particularly important in immune compromised patients. It is currently in Phase III clinical development by the German biopharmaceutical company AiCuris Anti-infective Cures AG.